Quotient Clinical and Upperton announce a spray drying partnership to deliver integrated formulation development and GMP manufacturing programs for poorly soluble drugs

news - upperton

Quotient Clinical, the Translational Pharmaceutics® company, and Upperton, the UK spray drying specialist, have announced a partnership to address drug delivery challenges. This venture will combine Upperton’s formulation development services with Quotient’s GMP manufacturing services.

Over 40% of candidate drugs in development are poorly soluble which leads to low oral bioavailability. Spray drying is a widely adopted and successful approach to addressing this issue. Mark Egerton, CEO of Quotient Clinical said “Spray drying is a key technology and is an established capability within our service portfolio. Upperton has more than 20 years’ spray drying expertise and this partnership will both reinforce our existing spray drying know-how and extend our capabilities into biologics, offering new and exciting opportunities”.

Richard Johnson, CEO and Founder of Upperton added “We are really pleased to announce this partnership with Quotient. It allows us to streamline the transfer of formulation development projects into pilot GMP manufacturing, better supporting our customers’ preclinical and clinical development needs. Our first joint program has already been successfully delivered and has demonstrated the time savings that can be achieved for our customers through our close working relationship with Quotient”.

About Quotient Clinical

Quotient Clinical offers unique services – based on its Translational Pharmaceutics® platform – that integrate formulation development, real-time drug product manufacturing and clinical testing, significantly reducing the time and cost of bringing a drug to market.

For more than 20 years, Quotient Clinical has brought innovation to drug product development programs for pharmaceutical and biotechnology customers worldwide. The company is based in purpose-built, fully integrated facilities in the UK, where formulation development, real-time GMP manufacturing and early clinical trials are performed in the same facility. It employs over 320 staff, offering a full range of support services, from study set-up right through to data analysis and reporting. Quotient Clinical was recently acquired by specialist healthcare investor GHO Capital who will support the future development of the company. 

About Upperton

Upperton Limited is a contract services company that specialises in the formulation and spray drying of pharmaceutical and biotechnology products.  Based in Nottingham, UK, Upperton has extensive spray drying capabilities and can offer clients a complete development service from early stage feasibility through to development and scale-up.

For further information, please contact:

Robin Bodicoat
Marketing Director
Quotient Clinical
Tel: +44 (0)115 931 5102